Bone events halt OncoMed early 'Wnt' studies; shares drop
This article was originally published in Scrip
Shares of OncoMed Pharmaceuticals plummeted 25% on 13 June after the cancer drug developer revealed it had voluntarily stopped patient enrollment and dosing in its ongoing Phase I trials testing two Wnt pathway inhibitors – vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28) – following reports of mild-to-moderate adverse bone-related events.
You may also be interested in...
The California biotech's Phase II pancreatic cancer candidate demcizumab failed to show benefit versus placebo for progression-free or overall survival. Meanwhile, Bayer decided not to exercise its options on a pair of Wnt pathway candidates under a 2010 collaboration with OncoMed.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.